Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIONTECH SE has 1 pending office action in Biotechnology & Pharmaceuticals. The record identifies 1 distinct examiner and 1 distinct art unit, concentrating the pending matter in one examination setting.
WEN, SHARON X is the busiest examiner, with 1 pending matter. Counsel can focus claim construction, technical support, and prior-art distinctions on one examiner’s review within the identified biotechnology art-unit context.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, JOHN DAVID | 1 | 61.1% | +28.3% |
| WEN, SHARON X | 1 | 56.8% | +32.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906448 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | MOORE, JOHN DAVID | 9d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17310459 | TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES | WEN, SHARON X | 36d overdue |
| 17906448 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | MOORE, JOHN DAVID | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17906448 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | MOORE, JOHN DAVID | 1638 | §101§102§112 | Non-Final OA | 9d overdue | Pending | Sep 15, 2022 |
| 17310459 | TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES | WEN, SHARON X | 1641 | §103Other | Final Rejection | 36d overdue | Pending | Aug 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIONTECH SE has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
John David Moore has the most, with 1 of BIONTECH SE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.